175 related articles for article (PubMed ID: 22165909)
1. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells.
Kalin JH; Butler KV; Akimova T; Hancock WW; Kozikowski AP
J Med Chem; 2012 Jan; 55(2):639-51. PubMed ID: 22165909
[TBL] [Abstract][Full Text] [Related]
2. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Histone Deacetylase 6 Reveals a Potent Immunosuppressant Effect in Models of Transplantation.
Ellis JD; Neil DA; Inston NG; Jenkinson E; Drayson MT; Hampson P; Shuttleworth SJ; Ready AR; Cobbold M
Transplantation; 2016 Aug; 100(8):1667-74. PubMed ID: 27222932
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Beier UH; Wang L; Han R; Akimova T; Liu Y; Hancock WW
Sci Signal; 2012 Jun; 5(229):ra45. PubMed ID: 22715468
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells.
de Zoeten EF; Wang L; Butler K; Beier UH; Akimova T; Sai H; Bradner JE; Mazitschek R; Kozikowski AP; Matthias P; Hancock WW
Mol Cell Biol; 2011 May; 31(10):2066-78. PubMed ID: 21444725
[TBL] [Abstract][Full Text] [Related]
8. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.
De Vreese R; Depetter Y; Verhaeghe T; Desmet T; Benoy V; Haeck W; Van Den Bosch L; D'hooghe M
Org Biomol Chem; 2016 Feb; 14(8):2537-49. PubMed ID: 26822143
[TBL] [Abstract][Full Text] [Related]
10. Ring-opened tetrahydro-γ-carbolines display cytotoxicity and selectivity with histone deacetylase isoforms.
Nepali K; Lee HY; Lai MJ; Ojha R; Wu TY; Wu GX; Chen MC; Liou JP
Eur J Med Chem; 2017 Feb; 127():115-127. PubMed ID: 28038324
[TBL] [Abstract][Full Text] [Related]
11. [New synthesis of highly selective inhibitor of histone deacetylase 6--N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3b]indol-5-ylmethyl)benzamide--Tubastatin A].
Kozlov MV; Kleĭmenova AA; Konduktorov KA; Kochetkov SN
Bioorg Khim; 2013; 39(1):117-20. PubMed ID: 23844513
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
13. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
[TBL] [Abstract][Full Text] [Related]
15. Beyond the Selective Inhibition of Histone Deacetylase 6.
Rodrigues DA; Thota S; Fraga CA
Mini Rev Med Chem; 2016; 16(14):1175-84. PubMed ID: 27121714
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors.
Morgen M; Steimbach RR; Géraldy M; Hellweg L; Sehr P; Ridinger J; Witt O; Oehme I; Herbst-Gervasoni CJ; Osko JD; Porter NJ; Christianson DW; Gunkel N; Miller AK
ChemMedChem; 2020 Jul; 15(13):1163-1174. PubMed ID: 32348628
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma.
Hou X; Wan H; Ai X; Shi Y; Ni Y; Tang W; Shi G
Clin Respir J; 2016 May; 10(3):371-9. PubMed ID: 25307458
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
19. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
Qu Y; Zhang B; Zhao L; Liu G; Ma H; Rao E; Zeng C; Zhao Y
Transpl Immunol; 2007 Apr; 17(3):153-61. PubMed ID: 17331841
[TBL] [Abstract][Full Text] [Related]
20. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
